Our new Highlights Video Series has you covered! Each EANM Committee shares its top-selected abstracts and must-attend sessions, giving you a quick, expert-curated preview of what not to miss at EANM’26.
Can't decide which sessions to attend?
EANM Artificial Intelligence Committee
Highlighted abstracts
| Abstract | Title | Session | Day | Time | Hall |
| OP-091 | A Full Monte Carlo Reconstruction Algorithm for Improved Precision via Dual-Photopeak Lu-177 SPECT Imaging | 305 | Oct. 18 | 09:45-11:15 | Hall B |
| OP-093 | Experimental and Monte Carlo-based assessment of collimator-induced X-rays in ¹⁷⁷Lu SPECT energy spectra | 305 | Oct. 18 | 09:45-11:15 | Hall B |
| OP-097 | Evaluation of Reduced Acquisition Times in ¹²³I-FP-CIT SPECT (DaTscan) Imaging | 305 | Oct. 18 | 09:45-11:15 | Hall B |
| OP-155 | Total Tumour-Burden Dosimetry in Patients Undergoing ¹⁷⁷Lu-PRRT | 505 | Oct. 18 | 15:00-16:30 | Hall B |
| OP-158 | PSMASegmentator: Open-source, AI-based software for automatic segmentation and biomarker extraction from PSMA PET/CT | 505 | Oct. 18 | 15:00-16:30 | Hall B |
| OP-227 | Real-world Clinical Evaluation of a Deep Learning-based Respiratory Motion Correction Algorithm of ¹⁸F-FDG PET/CT in Lung Lesions: A Three-year Follow-up Study | 605 | Oct. 18 | 16:45-18:15 | Hall B |
| OP-428 | Assessment of Large Language Model Performance in the Selection of Appropriate Tracers and Protocols for PET/CT Imaging | 1005 | Oct. 19 | 15:00-16:30 | Hall B |
| OP-434 | Can Foundation-Model Embeddings Simplify DAT-SPECT Analysis? A Feasibility Study Using BrainIAC in PD, Controls, and SWEDD | 1005 | Oct. 19 | 15:00-16:30 | Hall B |
| OP-551 | 3D nnU-Net Deep Learning Segmentation of ⁶⁸Ga-PSMA-11 PET/CT: Automated Prognostic Biomarker Extraction in Metastatic Castration-Resistant Prostate Cancer | 1205 | Oct. 20 | 08:00-09:30 | Hall B |
| OP-553 | Translating FDG and PSMA PET Reports into Segmentation Constraints via Large Language Model-Based Lesion Extraction | 1205 | Oct. 20 | 08:00-09:30 | Hall B |
| OP-554 | Multicentre validation of a deep learning model for Paget’s disease of bone lesion segmentation in bone scintigraphy | 1205 | Oct. 20 | 08:00-09:30 | Hall B |
| OP-558 | Multicenter assessment of an automated AI-based lesion segmentation tool for detecting lymphoma on whole-body FDG PET/CT | 1205 | Oct. 20 | 08:00-09:30 | Hall B |
| OP-607 | Optimising [¹⁷⁷Lu]Lu-DOTATATE Therapy: Virtual Trials of Dosimetry-Guided and Adaptive Dosing Strategies | 1305 | Oct. 20 | 09:45-11:15 | Hall B |
| OP-609 | A Multi-Network Consensus Framework for Reliable and Reproducible Deep Radiomics in PET-Based Lung Cancer Survival Prediction | 1305 | Oct. 20 | 09:45-11:15 | Hall B |
| OP-610 | AI-Driven Automated Deauville Scoring on FDG-PET/CT: A Transparent Decision-Support Tool | 1305 | Oct. 20 | 09:45-11:15 | Hall B |
| OP-612 | Automated quantitative analysis of FDG-PET/CT using AI-assisted PERCIST for response monitoring in metastatic breast cancer | 1305 | Oct. 20 | 09:45-11:15 | Hall B |
EANM Bone & Joint Committee
Highlighted abstracts
| Abstract | Title | Session | Day | Time | Hall |
| OP-328 | Ga-68 PSMA PET/CT in Treatment-Naïve Osteosarcoma: Baseline Tumour Characterisation, Metastatic Staging, and Correlation with Histopathological Response to Neoadjuvant Chemotherapy | 711 | Oct. 19 | 08:00-09:30 | Hall G1 |
| OP-329 | A Head-to-Head Comparative Study of 68Ga-DOTA-IBA and 18F-NaF PET/CT in Bone Metastases | 711 | Oct. 19 | 08:00-09:30 | Hall G1 |
| OP-330 | Phase I Dose-Escalation Study of [177Lu]Lu-P15-073 in Patients with Bone Metastases: Safety, Preliminary Antitumor Activity, and PET-Based Dose Individualization | 711 | Oct. 19 | 08:00-09:30 | Hall G1 |
EANM Cardiovascular Committee
Highlighted abstracts
| Abstract | Title | Session | Day | Time | Hall |
| EPS-032 | Clinical Factors and Imaging Characteristics of Abnormal Myocardial FAPI Uptake in Cancer Patients: A New Perspective for Visualizing Subclinical Myocardial Remodeling | 309 | Oct. 18 | 09:45-11:15 | Hall G2 |
| EPS-037 | Myocardial 99mTc-DPD Uptake Changes in Tafamidis-Treated Transthyretin Cardiac Amyloidosis. Preliminary Results from an Ongoing Research Project | 309 | Oct. 18 | 09:45-11:15 | Hall G2 |
| OP-420 | Macrophage‑targeted PET imaging in cardiac sarcoidosis: Temporal agreement between ⁶⁴Cu‑DOTATATE and ¹⁸F‑FDG | 1004 | Oct. 19 | 15:00-16:30 | Hall E2 |
| OP-421 | Fibroblast Activation Imaging by [18F]F-FAPI PET Predicts Recurrence After Atrial Fibrillation Ablation: A Pilot Study | 1004 | Oct. 19 | 15:00-16:30 | Hall E2 |
| OP-422 | Preserved risk stratification of lethal arrhythmic events using an ¹²³I-MIBG-based risk model in patients with and without ICD/CRT-D | 1004 | Oct. 19 | 15:00-16:30 | Hall E2 |
| OP-425 | [¹⁸F]F-AraG PET imaging detects early myocardial responses to cancer therapy | 1004 | Oct. 19 | 15:00-16:30 | Hall E2 |
| OP-769 | AL and ATTR Cardiac Amyloidosis Identified by 18 F-florbetaben-PET Detection of Cardiac and Multi-Organ Involvement | 1610 | Oct. 20 | 16:45-18:15 | Hall K |
| OP-770 | Prognostic Value of ¹⁸F-FAPI Positron Emission Tomography in Predicting Amyloid Light-Chain Cardiac Amyloidosis | 1610 | Oct. 20 | 16:45-18:15 | Hall K |
| OP-771 | Dual-Tracer ⁶⁸Ga-FAPI-04 and ¹⁸F-Florbetapir PET Reveals Distinct Pathologic Patterns and Prognostic Value in Light-Chain Cardiac Amyloidosis | 1610 | Oct. 20 | 16:45-18:15 | Hall K |
| OP-773 | Quantitative 99mTc-Pyrophosphate SPECT/CT Imaging for Monitoring Therapeutic Response in Transthyretin Cardiac Amyloidosis: The Role of SUVratios | 1610 | Oct. 20 | 16:45-18:15 | Hall K |
| OP-889 | Head-to-head Comparison of Multiple Cardiac Magnetic Resonance Parameters for the Detection of CMVD in Patients with INOCA: Validation with Integrated PET/MRI Scanner | 1808 | Oct. 21 | 09:45-11:15 | Hall F2 |
EANM Dosimetry Committee
Highlighted abstracts
| Abstract | Title | Session | Day | Time | Hall |
| EPS-003 | Absorbed dose threshold for soft tissue lesion complete response of differentiated thyroid cancer metastases treated with radioiodine: comparison between tumour control probability assessed with RECIST and ¹²⁴I PET | 209 | Oct. 18 | 08:00-09:30 | Hall G2 |
| EPS-010 | Quantitative Actinium-225 SPECT/CT Reconstruction: Insights from the ACTI-QUANT AAPM Grand Challenge 2025 | 209 | Oct. 18 | 08:00-09:30 | Hall G2 |
| OP-110 | Population-based single-time-point kidney TIA calculation in [¹⁷⁷Lu]Lu-PSMA-617 therapy: A multicenter study | 307 | Oct. 18 | 09:45-11:15 | Hall F1 |
| OP-111 | Single- and Dual-Time-Point Dosimetry for Radioligand Therapy: A Unified Framework Validated Across Short- and Long-Circulating Agents | 307 | Oct. 18 | 09:45-11:15 | Hall F1 |
| OP-357 | Comparative voxel-based dosimetry between pre-treatment SPECT/CT and post-treatment Total-Body ⁹⁰Y PET/CT in SIRT | 805 | Oct. 19 | 09:45-11:15 | Hall B |
| OP-365 | Avidination for Radionuclide Therapy in Nonpalpable Breast Cancer (ARTHE): model-based Monte Carlo dosimetry of ⁹⁰Y-DOTA-biotin locoregional therapy | 805 | Oct. 19 | 09:45-11:15 | Hall B |
| OP-678 | Dose-response Analysis in Patients with Gastroenteropancreatic Neuroendocrine Tumours Receiving ¹⁷⁷Lu-edotreotide | 1505 | Oct. 20 | 15:00-16:30 | Hall B |
| OP-684 | Cycle-to-Cycle Prediction of Absorbed Dose in [¹⁷⁷Lu]Lu-PSMA-617 Therapy Using Radiomic and Dosiomic Features from Prior SPECT/CT Imaging | 1505 | Oct. 20 | 15:00-16:30 | Hall B |
| OP-794 | First in-human dosimetry of [¹⁷⁷Lu]Lu-OncoACP3-DOTA and [¹⁷⁷Lu]Lu-RYZACP3-DOTA radiopharmaceutical therapy of advanced prostate cancer | 1705 | Oct. 21 | 08:00-09:30 | Hall B |
| OP-795 | Biodistribution and Dosimetry of [¹⁶¹Tb]Tb-DOTAGA-Glu-(FAPI)₂ in Advanced-Stage Solid Tumors: First-in-Human Experience | 1705 | Oct. 21 | 08:00-09:30 | Hall B |
EANM Inflammation & Infection Committee
Highlighted abstracts
| Abstract | Title | Session | Day | Time | Hall |
|
OP-451 |
Utility of Total Lesion Glycolysis Score on ¹⁸F-FDG-PET/CT for Diagnosis and Prognosis in Polymyalgia Rheumatica | 1007 | Oct. 19 | 15:00-16:30 | Hall F1 |
|
OP-816 |
Kinetic Modeling of Total-Body [¹⁸F]FDG-PET/CT for Crohn’s Disease: Preliminary Results of the CRODYNO Study | 1707 | Oct. 21 | 08:00-09:30 | Hall F1 |
EANM Neuroimaging Committee
Highlighted abstracts
| Abstract | Title | Session | Day | Time | Hall |
| OP-174 | Non-Inferiority of [¹⁸F]LBT-999 PET versus [¹²³I]FP-CIT SPECT for Dopamine Transporter Imaging in the Differential Diagnosis of Parkinson’s Disease and Essential Tremor: Results from the DATTEP Study | 507 | Oct. 18 | 15:00-16:30 | Hall F1 |
| OP-175 | First-in-Human Evaluation of [¹⁸F]ACI-15916, a New α-Synuclein PET Radioligand, in Healthy Volunteers and Individuals with α-Synucleinopathies | 507 | Oct. 18 | 15:00-16:30 | Hall F1 |
| OP-180 | Comparative Study of TSPO PET and susceptibility-sensitive MRI for Detecting Chronic Active Lesions in Multiple Sclerosis | 507 | Oct. 18 | 15:00-16:30 | Hall F1 |
| OP-307 | Radionuclide Therapy with [¹⁷⁷Lu]Lu-DOTATATE in Refractory Meningiomas: Results from the French Multicenter MELUTE Cohort | 707 | Oct. 19 | 08:00-09:30 | Hall F1 |
| OP-377 | Longitudinal Effects of Lecanemab on Aβ Clearance and Multimodal Brain Network Coupling Stratified by Baseline Tau Burden in Mild Cognitive Impairment and Early Alzheimer’s Disease | 807 | Oct. 19 | 09:45-11:15 | Hall F1 |
| OP-383 | Lecanemab treatment promotes imaging-defined resolution of neuroinflammation in early Alzheimer’s disease: a longitudinal [¹⁸F]DPA-714 PET/MR study | 807 | Oct. 19 | 09:45-11:15 | Hall F1 |
| OP-568 | Tau PET Fill States as Spatial Biomarkers for Alzheimer’s Disease Staging and Differential Diagnosis | 1207 | Oct. 20 | 08:00-09:30 | Hall F1 |
| OP-571 | Added value of semi-quantification on Tau-PET visual assessment in routine memory clinic practice | 1207 | Oct. 20 | 08:00-09:30 | Hall F1 |
| OP-878 | Astrocyte-PET in Alzheimer’s Disease Amyloid Cascade: Results from the ASTEROID cohort | 1807 | Oct. 21 | 09:45-11:15 | Hall F1 |
EANM Oncology & Theranostics Committee
Highlighted abstracts
| Abstract | Title | Session | Day | Time | Hall |
| OP-164 | [⁶⁸Ga]Ga-DPI-4452 (CA-IX peptide) PET/CT for Imaging Clear Cell Renal Cell Carcinoma: Interim Results from a Bicentre Registry | 506 | Oct. 18 | 15:00-16:20 | Hall C |
| OP-229 | Head-to-head comparison of ⁶⁸Ga-FAPI-46 and ¹⁸F-FDG PET/CT for the initial staging of invasive lobular breast cancer: a prospective study | 606 | Oct. 18 | 16:45-18:15 | Hall C |
| OP-262 | Comparison of Tumour- and Organ Absorbed Doses in ¹⁷⁷Lu SSTR Agonist and Antagonist PRRT for NETs across alternating treatment cycles: A single center experience | 611 | Oct. 18 | 16:45-18:15 | Hall G1 |
| OP-300 | Prospective Randomized intra-patient Comparison of Diagnostic Performance and Clinical Impact of Total-Body vs Short-Axial Field-of-View [⁶⁸Ga]Ga-PSMA-11 PET/CT in Biochemical Recurrent Prostate Cancer: the VAULT Study | 706 | Oct. 19 | 08:00-09:30 | Hall C |
| OP-302 | Prospective comparison of [⁶⁴Cu]Cu-SAR-bisPSMA vs [⁶⁸Ga]Ga-PSMA-11 PET/CT for biochemical recurrence of prostate cancer following radical prostatectomy (Co-PSMA trial) | 706 | Oct. 19 | 08:00-09:30 | Hall C |
| OP-457 | PSMA-REACH: Real-world effectiveness and treatment patterns of [¹⁷⁷Lu]Lu-PSMA-617 in patients with mCRPC | 1011 | Oct. 19 | 15:00-16:30 | Hall G1 |
| OP-464 | Safety and Efficacy of [¹⁶¹Tb]Tb-PSMA-I&T (9.5 GBq) Radioligand Therapy for mCRPC: Results from the Expanded VIOLET Phase I/II Study | 1011 | Oct. 19 | 15:00-16:30 | Hall G1 |
| OP-523 | Interim results from PTherpan-Lu trial: [¹⁷⁷Lu]Lu-DOTA-HYNIC-panPSMA radionuclide therapy for patients with metastatic castration-resistant prostate cancer | 1111 | Oct. 19 | 16:45-18:15 | Hall G1 |
| OP-621 | Contribution of [¹⁸F]AlF-FAPI-74 PET/CT in Clinically Challenging Oncologic Situations: Interim Analysis of a Prospective Multicenter Trial (FAPIDO) | 1306 | Oct. 20 | 09:45-11:15 | Hall C |
| OP-690 | Evaluation of Diagnostic Performance and Safety of Flotufolastat F-18 (XTR020) PSMA-Targeted PET Imaging in Biochemically Recurrent Prostate Cancer After Prior Therapy: A Single-arm, Multicenter Phase III Trial | 1506 | Oct. 20 | 15:00-16:30 | Hall C |
| OP-694 | ⁹⁹ᵐTc-MIP-1404 SPECT/CT for primary staging of prostate cancer (PROSTAMIP): a prospective randomized phase III trial | 1506 | Oct. 20 | 15:00-16:30 | Hall C |
| OP-748 | Impact of [⁶⁸Ga]Ga-PSMA-11 PET/CT in the diagnosis of prostate cancer in men with equivocal or non-suspicious findings on multi-parametric MRI (PRIMARY2): a multi-centre, phase III, randomised trial | 1606 | Oct. 20 | 16:45-18:15 | Hall C |
EANM Paediatrics Committee
Highlighted abstracts
| Abstract | Title | Session | Day | Time | Hall |
| OP-507 | Less is more: AI-enabled dose reduction in pediatric PET imaging | 1107 | Oct. 19 | 16:45-18:15 | Hall F1 |
| OP-509 | Quantifying the Invisible: A Novel PET Severity Score for Paediatric MOGAD Linking Metabolism to Disability in the Largest ¹⁸F-FDG PET-CT Series (n=30) | 1107 | Oct. 19 | 16:45-18:15 | Hall F1 |
| OP-624 | Beyond FDG: CAIX-Targeted PET Achieves Near-Complete Tumor Detection in Renal Cell Carcinoma | 1307 | Oct. 20 | 09:45-11:15 | Hall F1 |
EANM Physics Committee
Highlighted abstracts
| Abstract | Title | Session | Day | Time | Hall |
| OP-025 | Image-derived SUV and SUL for metadata-free quantification of whole-body static PET. | 205 | Oct. 18 | 08:00-09:30 | Hall B |
| OP-026 | First-in-human simultaneous Na¹²⁴I/¹⁸F-FDG dual-tracers PET imaging based on prompt gamma emissions | 205 | Oct. 18 | 08:00-09:30 | Hall B |
| OP-028 | Fast and Fitting-Free Ortho-Positronium Lifetime Tomography Without Prior Assumptions on Branching Ratios | 205 | Oct. 18 | 08:00-09:30 | Hall B |
| OP-032 | Validation of the equivalence of ultra-long axial field-of-view PET/CT without CT attenuation correction reconstruction in the diagnosis and treatment of lymphoma: A new strategy for reducing radiation dose | 205 | Oct. 18 | 08:00-09:30 | Hall B |
| OP-290 | From Calibration to Clinic: Province-Wide Implementation of Quantitative ¹⁷⁷Lu SPECT/CT for Post-treatment Imaging in British Columbia | 705 | Oct. 19 | 08:00-09:30 | Hall B |
| OP-293 | Towards reduced acquisition times for ¹⁷⁷Lu and ¹³¹I imaging using a dual-side CZT-based full-ring SPECT/CT system | 705 | Oct. 19 | 08:00-09:30 | Hall B |
| OP-295 | Harmonised multi‑centre cross‑calibration of ²¹¹At for preclinical and clinical studies within the EU-HORIZON-JU-IHI Accelerate.EU project | 705 | Oct. 19 | 08:00-09:30 | Hall B |
| OP-486 | Multi Tracer Spectral Analysis of Dynamic Large Axial Field of View PET/CT Studies | 1105 | Oct. 19 | 16:45-18:15 | Hall B |
| OP-487 | Towards Clinically Compatible Dynamic PET: Enabling Kinetic Analysis with 20-Minute Acquisitions | 1105 | Oct. 19 | 16:45-18:15 | Hall B |
| OP-491 | From Black Box to Physical Interpretation: A 3D-Printed Dynamic Phantom for Kinetic-Modelling Validation in Total-Body PET | 1105 | Oct. 19 | 16:45-18:15 | Hall B |
| OP-737 | Robustness of Long Axial Field of View PET to Defective Detector Blocks: Impact on Quantitative Accuracy and Clinical Tolerability | 1605 | Oct. 20 | 16:45-18:15 | Hall B |
EANM Radiation Protection Committee
Highlighted abstracts
| Abstract | Title | Session | Day | Time | Hall |
| OP-633 | Patient release after therapy with Lu-177 radiopharmaceuticals in HERCA member states | 1308 | Oct. 20 | 09:45-11:15 | Hall F2 |
| OP-634 | Machine-learning prediction of discharge timing after I-131 therapy for differentiated thyroid cancer | 1308 | Oct. 20 | 09:45-11:15 | Hall F2 |
| OP-635 | Early bedside count-rate monitoring to derive vigilance and urgent imaging in Lu-177-vipivotide tetraxetan (PSMA-617) and Lu-177-DOTATATE radioligand therapy | 1308 | Oct. 20 | 09:45-11:15 | Hall F2 |
EANM Radiopharmaceutical Sciences Committee
Highlighted abstracts
| Abstract | Title | Session | Day | Time | Hall |
| OP-016 | Photoacid-Activated ⁶⁴Cu-Doped Metal-Organic Frameworks Potentiate Radionuclide-Integrated Cuproptosis | 204 | Oct. 18 | 08:00-09:30 | Hall E2 |
| OP-082 | Evaluation of the therapeutic efficacy of ¹⁶¹Tb versus ¹⁷⁷Lu anti-CD30 radioimmunotherapy in a disseminated T-cell lymphoma mouse model | 304 | Oct. 18 | 09:45-11:15 | Hall E2 |
| OP-085 | Enhancing Prostate Cancer Care Through Tandem PSMA- and GRPR-targeted Radionuclide Treatment | 304 | Oct. 18 | 09:45-11:15 | Hall E2 |
| OP-150 | Production and Characterization of ²²⁸Th to Support ²¹²Pb/²¹²Bi Targeted Alpha Therapy Research and Development | 504 | Oct. 18 | 15:00-16:30 | Hall E2 |
| OP-675 | Theranostic Potential of VHH Domains (Nanobodies) Targeting MUC16 Expression in Pancreatic Cancer | 1504 | Oct. 20 | 15:00-16:30 | Hall E2 |
| OP-726 | Extraction, Radiolabeling and Preclinical Evaluation of Novel [¹⁷⁷Lu]Lu-KRT83/31 for FAP-Targeted Radioligand Theranostics of Solid Tumor | 1604 | Oct. 20 | 16:45-18:15 | Hall E2 |
| OP-730 | Design, Synthesis, Preclinical Characterization and First-in-Human Evaluation of [⁶⁸Ga]Ga-NYM052, a Novel Fibroblast Activation Protein-Targeted Radiotracer | 1604 | Oct. 20 | 16:45-18:15 | Hall E2 |
| OP-785 | In vitro evaluation of designed ankyrin repeat protein (DARPin)-peptide nucleic acid (PNA) chimeras, created by microbial transglutaminase ligation for radionuclide pretargeting | 1704 | Oct. 21 | 08:00-09:30 | Hall E2 |
EANM Technologists Committee
Highlighted abstracts
| Abstract | Title | Session | Day | Time | Hall |
| OP-326 | Beyond the Vein: Technologist-Led Development of a Low-Dose Oral [¹⁸F]FDG Protocol on Long-axial Field-of-view PET/CT | 710 | Oct. 19 | 08:00-09:30 | Hall K |
| TEPS-020 | Expanding the Role of PhD Nuclear Medicine Technologists in Clinical Nuclear Medicine and University Education: Opportunities in Bosnia and Herzegovina | 1010 | Oct. 19 | 15:00-16:30 | Hall K |
| OP-641 | Combination of [¹⁷⁷Lu]Lu-PSMA-617 and [¹⁷⁷Lu]Lu-TBM in Prostate Cancer: A Comparative Study of Safety and Survival Outcomes | 1310 | Oct. 20 | 09:45-11:15 | Hall K |
| OP-646 | Impact of PET Reconstruction Protocols on ⁹⁰Y-SIRT Dosimetry Accuracy: A Monte Carlo Validation Study Using LAFOV PET | 1310 | Oct. 20 | 09:45-11:15 | Hall K |
| EP-1545 | Implementing CXCR4 theranostics in clinical routine: Challenges from PET/CT acquisition to radioligand therapy | e-Poster | – | – | – |
EANM Thyroid Committee
Highlighted abstracts
| Abstract | Title | Session | Day | Time | Hall |
| OP-250 | ⁶⁸Ga-labeled PET tracers versus ¹⁸F-FDG for metastatic detection in thyroid cancer patients after ¹³¹I therapy: a comparative analysis of ⁶⁸Ga-PSFA, ⁶⁸Ga-FAPI and ⁶⁸Ga-PSMA | 608 | Oct. 18 | 16:45-18:15 | Hall F2 |
| OP-254 | ⁶⁸Ga-NODAGA-RGD PET/CT Predicts Efficacy of Neoadjuvant Therapy in Newly Diagnosed Locally Advanced Thyroid Cancer | 608 | Oct. 18 | 16:45-18:15 | Hall F2 |
| OP-392 | Prognostic Value of the Number of Metastatic Nodes in Pediatric Papillary Thyroid Cancer Patients: A Real-Life Multicenter Study | 808 | Oct. 19 | 09:45-11:15 | Hall F2 |
| EPS-129 | Ga-68 Trivehexin PET/CT as a First-Line and rescue imaging modality in Primary Hyperparathyroidism: Comparative Analysis with ⁹⁹ᵐTc-Sestamibi and the Novel Incidental Detection of Concomitant Breast Malignancy | 1009 | Oct. 19 | 15:00-16:30 | Hall G2 |
| OP-752 | Positive Sestamibi SPECT/CT alone is sufficient without routine Ultrasound for pre-operative Parathyroid adenoma localisation in Primary Hyperparathyroidism | 1607 | Oct. 20 | 16:45-18:15 | Hall F1 |
| OP-756 | Optimal timing of ¹⁸F-FCH PET/CT in preoperative localization of parathyroid adenoma: a comparative assessment of 10 versus 60 minutes acquisition | 1607 | Oct. 20 | 16:45-18:15 | Hall F1 |
| OP-759 | Head-to-head Comparison of ⁶⁸Ga-DOTANOC PET/CT and ⁹⁹ᵐTc-MIBI with SPECT/CT for Localization of MEN-associated Primary Hyperparathyroidism: A Paired Analysis | 1607 | Oct. 20 | 16:45-18:15 | Hall F1 |
| OP-827 | Comparison of [⁶⁸Ga]Ga-CTR-FAPI PET-CT with Conventional Imaging in Recurrent/Metastatic Medullary Thyroid Carcinoma | 1708 | Oct. 21 | 08:00-09:30 | Hall F2 |
| EP-0798 | Cost-effectiveness of preoperative parathyroid imaging in primary hyperparathyroidism | e-poster | – | – | – |
| EP-0798a | Diagnostic Performance of Imaging Modalities for Preoperative Localisation of Hyperfunctioning Parathyroid Glands in Hyperparathyroidism: A Synthesis of Meta-Analyses from the Past Decade | e-poster | – | – | – |
EANM Translational Molecular Imaging & Therapy
Highlighted abstracts
| Abstract | Title | Session | Day | Time | Hall |
| OP-280 | Bicyclic peptide-based EphA2-targeted PET in pancreatic cancer: first-in-human safety, biodistribution and dosimetry | 704 | Oct. 19 | 08:00-09:30 | Hall E2 |
| OP-348 | Advancing ¹¹⁹Sb Auger Radiotherapy: Production, Purification, Novel Chelation, and Preliminary Therapeutic Evaluation in Colorectal Cancer | 804 | Oct. 19 | 09:45-11:15 | Hall E2 |
| OP-355 | Targeting ALDH1A1 for the non-invasive detection and treatment of therapy-resistant cancers | 804 | Oct. 19 | 09:45-11:15 | Hall E2 |
| OP-478 | Comparative evaluation of [²²⁵Ac]Ac- and [¹⁷⁷Lu]Lu-DOTA-hG250 targeted radionuclide therapy and combination with PD1 blockade in a preclinical renal cell carcinoma model | 1104 | Oct. 19 | 16:45-18:15 | Hall E2 |
| OP-482 | Targeted Killing of Tumor Associated Macrophages with a Novel [¹⁷⁷Lu]Lu-Nanomedicine Prolongs Survival and Unlocks Checkpoint Inhibition in an Orthotopic Pancreatic Cancer Model | 1104 | Oct. 19 | 16:45-18:15 | Hall E2 |